Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
$VOR insiders have traded $VOR stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales. Here’s a ...
Vor Bio has appointed Dr. Qing Zuraw as Chief Development Officer, effective immediately, bringing over 25 years of experience in clinical development of autoimmune diseases. Dr. Zuraw previously held ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results